By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Doxapram (monograph)
Drugs

Doxapram (monograph)

https://themeditary.com/drug/doxapram-monograph-8311.html
Medically Reviewed by Glamora Samuels, MD TheMediTary.Com | Reviewed: Aug 25, 2023  Additional Content by TheMediTary.Com

Generic name: dopram

Availability: Prescription only

Pregnancy & Lactation: Risk data available

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

What is Doxapram (monograph)?

Introduction

CNS stimulant; a monohydrated pyrrolidinone derivative.

Uses for Doxapram

Postanesthetic Respiratory Depression

Treatment of drug-induced postanesthetic respiratory depression or apnea not caused by skeletal muscle relaxants.

Other supportive therapy preferred due to questionable benefit and high potential for toxicity with doxapram. Limited role due to availability of safer and shorter-acting anesthetic agents.

Drug-induced CNS Depression

Has been used in conjunction with supportive measures to stimulate respiration and hasten arousal in patients with respiratory and CNS depression secondary to drug overdose (e.g., barbiturates, opiate analgesics, general anesthetics).

However, use as an analeptic is strongly discouraged by most clinicians; analeptic therapy largely abandoned in favor of intensive supportive care (e.g., mechanical ventilation, oxygenation, cardiovascular support) and specific antidotes (e.g., pure opiate antagonists).

Acute Hypercapnia Associated with COPD

Short-term use in patients with acute respiratory insufficiency associated with COPD.

Role in such patients is limited; other supportive therapy (i.e., noninvasive ventilation using either negative- or positive-pressure device) is preferred.

Neonatal Apnea

Has been used for the treatment of neonatal apnea† [off-label], principally in combination with theophylline or caffeine.

Limited support for this use; no apparent advantage over methylxanthines and risk of substantial adverse effects with doxapram therapy. The commercially available injection contains benzyl alcohol; use of this preparation in neonates is not recommended. (See Pediatric Use under Cautions.)

Other Uses

Should not be used in conjunction with mechanical ventilation.

Doxapram Dosage and Administration

General

  • Establish adequate airway and oxygenation prior to administration; take measures to prevent vomiting and aspiration.

  • Use minimum effective dosage to avoid adverse effects.

  • Monitor BP, heart rate, and deep tendon reflexes; adjust dosage or rate of infusion accordingly. Monitor for recurrence of unconsciousness or development of respiratory depression; provide supportive care as required.

Administration

IV Administration

For solution and drug compatibility information, see Compatibility under Stability.

Administer by IV injection or IV infusion.

Predictable blood gas patterns in patients with COPD and acute hypercapnia are more readily established with IV infusion therapy.

Avoid extravasation and repeated use of a single injection site to minimize local reactions and thrombophlebitis.

Dilution

Prepare 1-mg/mL solution by adding 250 mg of doxapram hydrochloride (12.5 mL) to 250 mL of 5% dextrose, 10% dextrose, or 0.9% sodium chloride injection.

Prepare 2-mg/mL solution by adding 400 mg of doxapram hydrochloride (20 mL) to 180 mL of 5% dextrose, 10% dextrose, or 0.9% sodium chloride injection.

Rate of Administration

Rapid infusion may result in hemolysis; infuse diluted solution at slow rate.

Postanesthetic use: Initiate IV infusion with 1-mg/mL solution at a rate of approximately 5 mg/minute until desired response achieved; usual maintenance rate is 1–3 mg/minute.

Acute hypercapnia associated with COPD: Initiate IV infusion with 2-mg/mL solution at a rate of 1–2 mg/minute; may increase to maximum rate of 3 mg/minute.

Dosage

Available as doxapram hydrochloride; dosage expressed in terms of the salt.

Pediatric Patients

Postanesthetic Respiratory Depression
IV Injection

Children ≥12 years of age: 0.5–1 mg/kg as a single injection; may repeat every 5 minutes to a maximum total dosage of 2 mg/kg.

IV Infusion

Children ≥12 years of age: 0.5–1 mg/kg, up to a maximum dosage of 4 mg/kg.

Acute Hypercapnia Associated with COPD
IV Infusion

Children ≥12 years of age: Initiate at a rate of 1–2 mg/minute; increase to a maximum rate of 3 mg/minute if indicated. Continuation beyond a single 2-hour infusion not recommended.

Adults

Postanesthetic Respiratory Depression
IV Injection

0.5–1 mg/kg as a single injection; may repeat every 5 minutes to a maximum total dosage of 2 mg/kg.

IV Infusion

0.5–1 mg/kg, up to a maximum dosage of 4 mg/kg.

Acute Hypercapnia Associated with COPD
IV Infusion

Initiate at a rate of 1–2 mg/minute; increase to a maximum rate of 3 mg/minute if indicated. Continuation beyond a single 2-hour infusion not recommended.

Prescribing Limits

Pediatric Patients

Postanesthetic Respiratory Depression
IV Injection

Children ≥12 years of age: Maximum 1.5 mg/kg for a single injection, 2-mg/kg total dosage for repeat injections; do not exceed 3 g daily.

IV Infusion

Children ≥12 years of age: Maximum 4 mg/kg; do not exceed 3 g daily.

Acute Hypercapnia Associated with COPD
IV Infusion

Children ≥12 years of age: Maximum 3 mg/minute. Limit use to a single 2-hour infusion.

Adults

Postanesthetic Respiratory Depression
IV Injection

Maximum 1.5 mg/kg for a single injection, 2-mg/kg total dosage for repeat injections; do not exceed 3 g daily.

IV Infusion

Maximum 4 mg/kg; do not exceed 3 g daily.

Acute Hypercapnia Associated with COPD
IV Infusion

Maximum 3 mg/minute. Limit use to a single 2-hour infusion.

Special Populations

No special population dosage recommendations at this time.

Detailed Doxapram dosage information

Warnings

Contraindications

  • Known hypersensitivity to doxapram or any ingredient in the formulation.

  • Seizure disorders.

  • Suspected or confirmed pulmonary embolism.

  • Mechanical disorders of ventilation (e.g., mechanical obstruction, muscle paresis, flail chest, pneumothorax, acute bronchial asthma, pulmonary fibrosis or other restrictive lung diseases).

  • Head injury, cerebrovascular accident, or cerebral edema.

  • Substantial cardiovascular impairment (i.e., uncompensated heart failure, severe CAD).

  • Severe hypertension including that associated with hyperthyroidism or pheochromocytoma. (See Postanesthetic Use under Cautions.)

Warnings/Precautions

Warnings

Benzyl Alcohol in Neonates

Doxapram hydrochloride injection contains benzyl alcohol as a preservative, which has been associated with toxicity (including deaths) in neonates. Use of this preparation in neonates is not recommended. (See Pediatric Use under Cautions.)

Mechanical Ventilation

Do notuse doxapram in conjunction with mechanical ventilation.

Postanesthetic Use

Doxapram is not an antagonist to muscle relaxants nor a specific opiate antagonist. Assess adequacy of ventilation with specific tests (e.g., peripheral nerve stimulation, airway pressures, head lift, pulse oximetry, end-tidal carbon dioxide) prior to use.

Narcosis may recur; observe patient closely until fully alert for 0.5–1 hour.

Concomitant use with a volatile general anesthetic may increase potential for arrhythmias. (See Specific Drugs under Interactions.)

Use with caution in patients with hypermetabolic states (e.g., hyperthyroidism, pheochromocytoma).

Drug-Induced CNS and Respiratory Depression

May not be effective in patients with severe CNS or respiratory depression; manufacturers state that doxapram may be used adjunctively with established supportive and resuscitative measures.

If no response, perform neurologic evaluation to identify other potential causes of sustained coma.

COPD

Do not increase rate of infusion to lower carbon dioxide tension.

Arrhythmias have been reported in patients with acute respiratory failure secondary to COPD. Use with caution in these patients.

To prevent respiratory acidosis in patients with COPD, monitor arterial blood gases at baseline and every 30 minutes. Discontinue drug and initiate mechanical ventilation if arterial blood gases deteriorate.

Use does not reduce need for supplemental oxygen.

General Precautions

Cardiovascular Effects

Possible changes in heart rate, lowered T-waves, and dysrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, QT interval prolongation). Use with caution and monitor cardiac rhythm.

Increases in BP usually are modest, but substantial increases reported. Avoid use in patients with severe hypertension. (See Contraindications under Cautions.)

Chest pain and tightness in chest also reported.

Discontinue drug if sudden hypotension develops.

Respiratory Effects

Establish and protect airways.

Discontinue drug if sudden dyspnea develops.

Lowered carbon dioxide tension induced by hyperventilation may cause cerebral vasoconstriction and decreased cerebral circulation. Pressor effect on pulmonary circulation may lead to decreased arterial oxygen tension. Monitor arterial blood gases.

CNS Effects

May cause seizures and other adverse effects due to general CNS stimulation. Anticonvulsants, oxygen, and resuscitative equipment should be readily available; carefully observe patient and administer drug slowly if treatment continued.

Local Effects

Potential for local reactions including thrombophlebitis; administer dilute solutions at a slow rate, prevent extravasation, and avoid repeated use of a single injection site.

Hemolysis

Rapid infusion may result in hemolysis. (See Rate of Administration under Dosage and Administration.)

Specific Populations

Pregnancy

Category B.

Lactation

Not known whether doxapram is distributed into milk; however, molecular weight of free base suggests drug may be distributed into milk.

Benzyl alcohol in commercial preparation is associated with toxicity in neonates; caution if used in nursing women. (See Pediatric Use under Cautions.)

Pediatric Use

Safety and efficacy not established in children <12 years of age.

Each mL of doxapram hydrochloride injection contains 9 mg of benzyl alcohol; use of this preparation in neonates is not recommended. Although a causal relationship has not been established, large amounts of benzyl alcohol (100–400 mg/kg daily) have been associated with toxicity in neonates.

Hepatic Impairment

Use with caution. Possible decrease in rate of metabolism or clearance in patients with substantial hepatic impairment.

Renal Impairment

Use with caution. Possible decrease in rate of metabolism or clearance in patients with substantial renal impairment.

Common Adverse Effects

Cough, dyspnea, tachypnea, headache, dizziness, apprehension, hypertension, flushing, sweating, nausea, vomiting, diarrhea, urinary retention, muscle spasticity.

How should I use Doxapram (monograph)

General

  • Establish adequate airway and oxygenation prior to administration; take measures to prevent vomiting and aspiration.

  • Use minimum effective dosage to avoid adverse effects.

  • Monitor BP, heart rate, and deep tendon reflexes; adjust dosage or rate of infusion accordingly. Monitor for recurrence of unconsciousness or development of respiratory depression; provide supportive care as required.

Administration

IV Administration

For solution and drug compatibility information, see Compatibility under Stability.

Administer by IV injection or IV infusion.

Predictable blood gas patterns in patients with COPD and acute hypercapnia are more readily established with IV infusion therapy.

Avoid extravasation and repeated use of a single injection site to minimize local reactions and thrombophlebitis.

Dilution

Prepare 1-mg/mL solution by adding 250 mg of doxapram hydrochloride (12.5 mL) to 250 mL of 5% dextrose, 10% dextrose, or 0.9% sodium chloride injection.

Prepare 2-mg/mL solution by adding 400 mg of doxapram hydrochloride (20 mL) to 180 mL of 5% dextrose, 10% dextrose, or 0.9% sodium chloride injection.

Rate of Administration

Rapid infusion may result in hemolysis; infuse diluted solution at slow rate.

Postanesthetic use: Initiate IV infusion with 1-mg/mL solution at a rate of approximately 5 mg/minute until desired response achieved; usual maintenance rate is 1–3 mg/minute.

Acute hypercapnia associated with COPD: Initiate IV infusion with 2-mg/mL solution at a rate of 1–2 mg/minute; may increase to maximum rate of 3 mg/minute.

Dosage

Available as doxapram hydrochloride; dosage expressed in terms of the salt.

Pediatric Patients

Postanesthetic Respiratory Depression
IV Injection

Children ≥12 years of age: 0.5–1 mg/kg as a single injection; may repeat every 5 minutes to a maximum total dosage of 2 mg/kg.

IV Infusion

Children ≥12 years of age: 0.5–1 mg/kg, up to a maximum dosage of 4 mg/kg.

Acute Hypercapnia Associated with COPD
IV Infusion

Children ≥12 years of age: Initiate at a rate of 1–2 mg/minute; increase to a maximum rate of 3 mg/minute if indicated. Continuation beyond a single 2-hour infusion not recommended.

Adults

Postanesthetic Respiratory Depression
IV Injection

0.5–1 mg/kg as a single injection; may repeat every 5 minutes to a maximum total dosage of 2 mg/kg.

IV Infusion

0.5–1 mg/kg, up to a maximum dosage of 4 mg/kg.

Acute Hypercapnia Associated with COPD
IV Infusion

Initiate at a rate of 1–2 mg/minute; increase to a maximum rate of 3 mg/minute if indicated. Continuation beyond a single 2-hour infusion not recommended.

Prescribing Limits

Pediatric Patients

Postanesthetic Respiratory Depression
IV Injection

Children ≥12 years of age: Maximum 1.5 mg/kg for a single injection, 2-mg/kg total dosage for repeat injections; do not exceed 3 g daily.

IV Infusion

Children ≥12 years of age: Maximum 4 mg/kg; do not exceed 3 g daily.

Acute Hypercapnia Associated with COPD
IV Infusion

Children ≥12 years of age: Maximum 3 mg/minute. Limit use to a single 2-hour infusion.

Adults

Postanesthetic Respiratory Depression
IV Injection

Maximum 1.5 mg/kg for a single injection, 2-mg/kg total dosage for repeat injections; do not exceed 3 g daily.

IV Infusion

Maximum 4 mg/kg; do not exceed 3 g daily.

Acute Hypercapnia Associated with COPD
IV Infusion

Maximum 3 mg/minute. Limit use to a single 2-hour infusion.

Special Populations

No special population dosage recommendations at this time.

Detailed Doxapram dosage information
Doxapram (monograph) Dosage information (more detail)

What other drugs will affect Doxapram (monograph)?

Specific Drugs

Drug

Interaction

Comments

Anesthetics, inhalation (known to sensitize myocardium to catecholamines)

May increase potential for arrhythmias including ventricular tachycardia and ventricular fibrillation

Increased BUN and albuminuria observed

Delay administration of doxapram until anesthetic excreted

Importance of observed increase in BUN and albuminuria not established

CNS depressants

Increased BUN and albuminuria observed

Importance not established

MAO inhibitors

Possible synergistic pressor effect

Use with caution

Neuromuscular blocking agents

May temporarily mask residual effects of muscle relaxants

Use with caution

Sympathomimetic agents

Possible synergistic pressor effect

Use with caution

Theophyllines (e.g., aminophylline)

Possible increased skeletal muscle activity, agitation, and hyperactivity

More about Doxapram (monograph) (Dopram)

Dosage information
Doxapram (monograph) Side Effects
During pregnancy
Dopram Prescribing Information
Drug images
Side effects
Drug class: Drugs

Related treatment guides

Respiratory Depression
Share this Article
Contents
Uses Warnings Before Taking Dosage Side effects Interactions
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by